--- title: "Is It Time To Revisit Lantheus Holdings (LNTH) After Its Recent Share Price Swings?" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/280029750.md" description: "Lantheus Holdings (LNTH) is currently priced at approximately $76.43, showing a mixed return profile with a 4.6% gain over the last 30 days but a 21.8% decline over the past year. Analysts suggest the stock is undervalued by 54.5% based on a Discounted Cash Flow (DCF) analysis, estimating an intrinsic value of $168.16 per share. Additionally, the company's P/E ratio of 21.14x indicates it is undervalued compared to industry averages. Investors are encouraged to consider various narratives for future growth and valuation." datetime: "2026-03-21T18:37:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280029750.md) - [en](https://longbridge.com/en/news/280029750.md) - [zh-HK](https://longbridge.com/zh-HK/news/280029750.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280029750.md) | [English](https://longbridge.com/en/news/280029750.md) # Is It Time To Revisit Lantheus Holdings (LNTH) After Its Recent Share Price Swings? - If you are wondering whether Lantheus Holdings at around US$76.43 is priced attractively or already reflects its potential, the current valuation picture is worth a closer look. - The stock shows a mixed return profile, with a 4.6% gain over the last 30 days and a 13.6% gain year to date, set against a 21.8% decline over the past year and a 3 year return of a 6.1% decline. - Recent coverage has focused on Lantheus Holdings as a medical imaging and diagnostics player, highlighting how sentiment around healthcare demand and reimbursement trends can feed into expectations for the business. This context helps explain why the share price can shift quickly as investors reassess both risk and potential across different time frames. - Lantheus Holdings currently has a valuation score of 4 out of 6. This means it screens as undervalued on most of the checks used. The rest of this article will compare those traditional valuation approaches while pointing to a more complete way to think about value at the end. Find out why Lantheus Holdings's -21.8% return over the last year is lagging behind its peers. ### Approach 1: Lantheus Holdings Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes the cash Lantheus Holdings is expected to generate in the future, then discounts those amounts back to what they are worth in today’s dollars. Lantheus Holdings last twelve month Free Cash Flow stands at about $298.3 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates point to Free Cash Flow reaching $540.0 million in 2030, with intermediate projections such as $360.3 million in 2026 and $474.9 million in 2028. Simply Wall St extends analyst estimates beyond the usual 5 year window by gradually moderating growth in the outer years. When all those future cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $168.16 per share. Compared with a recent share price around $76.43, this suggests the stock appears roughly 54.5% undervalued based on this DCF framework. **Result: UNDERVALUED** Our Discounted Cash Flow (DCF) analysis suggests Lantheus Holdings is undervalued by 54.5%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks. LNTH Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Lantheus Holdings. ### Approach 2: Lantheus Holdings Price vs Earnings For profitable companies, the P/E ratio is a common way to think about what you are paying for each dollar of earnings. This makes it a practical cross check against a DCF model. What counts as a “normal” or “fair” P/E usually reflects how the market views a company’s growth potential and risk profile. Higher growth and lower perceived risk often support higher multiples, while slower growth or higher risk can point to lower ones. Lantheus Holdings currently trades on a P/E of about 21.14x. That sits close to the Medical Equipment industry average of around 26.87x and very close to the peer group average of about 20.95x. This suggests the market is broadly in line with how it prices similar earnings streams in this space. Simply Wall St’s Fair Ratio for Lantheus Holdings is 23.84x. This is a proprietary estimate of what the P/E might be given factors such as its earnings growth profile, industry, profit margins, market capitalization and specific risks. It tends to be more tailored than a simple comparison with peers or the wider industry because it explicitly folds those business characteristics into the assessment. Comparing the current 21.14x P/E with the 23.84x Fair Ratio indicates that the shares screen as undervalued on this earnings based yardstick. **Result: UNDERVALUED** NasdaqGM:LNTH P/E Ratio as at Mar 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. ## Upgrade Your Decision Making: Choose your Lantheus Holdings Narrative Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced as a simple tool that lets you write a clear story about Lantheus Holdings, connect that story to explicit assumptions for future revenue, earnings and margins, and see how those assumptions translate into a Fair Value. This can then be compared with the current price on Simply Wall St's Community page, where Narratives are updated when new earnings or news arrive and can differ widely. For example, one view may use a Fair Value of US$114.00 based on higher growth and margins, and another may use US$63.00 based on much slower growth and tighter margins. This can help you decide whether the current US$76.43 price looks high or low relative to the specific story you find most reasonable. For Lantheus Holdings, here are previews of two leading Lantheus Holdings narratives for you to review: **🐂 Lantheus Holdings Bull Case** Fair value in this bullish narrative: about US$84.62 per share. At the recent US$76.43 price, the stock sits roughly 9.7% below that fair value estimate. Revenue growth assumption in this narrative: 7.10% a year. - Alzheimer's and prostate cancer imaging, along with products like Neuraceq, MK 6240 and new PSMA PET agents, are presented as ways to broaden the portfolio and support higher earnings if execution goes to plan. - Acquisitions such as Evergreen and Life Molecular Imaging are built into the story as a way to support volume growth and potential margin improvement across radiopharmaceutical and neuroimaging markets. - The narrative still highlights risks around pricing pressure, PYLARIFY concentration, reimbursement shifts and integration challenges, so the upside case depends on management meeting specific growth and margin targets. **🐻 Lantheus Holdings Bear Case** Fair value in this cautious narrative: about US$76.00 per share. At the recent US$76.43 price, the stock sits roughly 0.6% above that fair value estimate. Revenue growth assumption in this narrative: 3.34% a year. - Pricing pressure in PSMA PET imaging and reimbursement constraints are central to the thesis, with margins and core product revenues treated as vulnerable if competition and discounting continue. - New products and partnerships are included, but the narrative assumes slower adoption, potential delays and higher integration costs that could limit the benefit to revenue and profitability. - Concentration in a few products such as PYLARIFY and DEFINITY, along with policy and regulatory uncertainty, is viewed as a source of ongoing revenue volatility and earnings risk. If you want to see how other investors connect these kinds of assumptions to their own valuation ranges and risk views, you can read the full set of community narratives for Lantheus Holdings to compare against your own expectations. Do you think there's more to the story for Lantheus Holdings? Head over to our Community to see what others are saying! NasdaqGM:LNTH 1-Year Stock Price Chart _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### 相關股票 - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [Lantheus (LNTH.US)](https://longbridge.com/zh-HK/quote/LNTH.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) ## 相關資訊與研究 - [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/zh-HK/news/281015927.md) - [Merck's Enlicitide Decanoate Shows Greater LDL-C Reduction Than Oral Non-Statins At 8 Weeks](https://longbridge.com/zh-HK/news/281051985.md) - [Arcutis Reports New Positive Phase 2 Results For ZORYVE Cream In Infant Atopic Dermatitis](https://longbridge.com/zh-HK/news/280971278.md) - [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/zh-HK/news/281024362.md) - [Bayer Announces Approval Of New Indication For Kerendia In The EU](https://longbridge.com/zh-HK/news/280969658.md)